Flossbach Von Storch SE Buys Shares of 4,210,978 Zoetis Inc. $ZTS

Flossbach Von Storch SE bought a new position in Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,210,978 shares of the company’s stock, valued at approximately $302,601,000. Zoetis comprises about 1.4% of Flossbach Von Storch SE’s investment portfolio, making the stock its 24th largest position. Flossbach Von Storch SE owned approximately 1.00% of Zoetis as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Wealthfront Advisers LLC boosted its holdings in Zoetis by 80.2% during the second quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock worth $5,469,000 after buying an additional 33,873 shares in the last quarter. Main Street Financial Solutions LLC bought a new stake in shares of Zoetis during the 2nd quarter worth $3,819,000. First National Bank of Omaha grew its holdings in shares of Zoetis by 16.5% in the 2nd quarter. First National Bank of Omaha now owns 3,882 shares of the company’s stock worth $284,000 after acquiring an additional 551 shares during the last quarter. Meeder Advisory Services Inc. lifted its holdings in shares of Zoetis by 21.6% during the second quarter. Meeder Advisory Services Inc. now owns 10,895 shares of the company’s stock valued at $783,000 after purchasing an additional 1,938 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc boosted its position in shares of Zoetis by 124.9% in the 2nd quarter. Texas Capital Bank Wealth Management Services Inc now owns 100,046 shares of the company’s stock valued at $7,189,000 after purchasing an additional 55,562 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $76.78 on Thursday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a one year low of $71.00 and a one year high of $160.48. The business’s 50-day moving average price is $75.92 and its two-hundred day moving average price is $97.81. The company has a market capitalization of $31.73 billion, a P/E ratio of 12.65, a price-to-earnings-growth ratio of 1.73 and a beta of 0.74.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts anticipate that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on ZTS. Morgan Stanley set a $85.00 price objective on Zoetis in a report on Friday, August 7th. Barclays reduced their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Stifel Nicolaus decreased their price objective on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research note on Friday, June 26th. Argus reiterated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Finally, TD Cowen reduced their target price on Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.